FI116882B - Användning av en pyridazinonförening för framställning av ett medel för profylax eller behandling av tromboxan A2-medlade sjukdomar - Google Patents

Användning av en pyridazinonförening för framställning av ett medel för profylax eller behandling av tromboxan A2-medlade sjukdomar Download PDF

Info

Publication number
FI116882B
FI116882B FI963264A FI963264A FI116882B FI 116882 B FI116882 B FI 116882B FI 963264 A FI963264 A FI 963264A FI 963264 A FI963264 A FI 963264A FI 116882 B FI116882 B FI 116882B
Authority
FI
Finland
Prior art keywords
pyridazinone
compound
chloro
txa2
chlorophenyl
Prior art date
Application number
FI963264A
Other languages
English (en)
Finnish (fi)
Other versions
FI963264A (sv
FI963264A0 (sv
Inventor
Ruriko Ikegawa
Teruaki Imada
Norifumi Nakamura
Keizo Tanikawa
Nobutomo Tsuruzoe
Original Assignee
Nissan Chemical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nissan Chemical Ind Ltd filed Critical Nissan Chemical Ind Ltd
Publication of FI963264A publication Critical patent/FI963264A/sv
Publication of FI963264A0 publication Critical patent/FI963264A0/sv
Application granted granted Critical
Publication of FI116882B publication Critical patent/FI116882B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Confectionery (AREA)
  • Pyridine Compounds (AREA)

Claims (4)

1. Användning av en pyridazinonförening med formeJ oi* (D iO-' i vilken R1, R2 och R3 är envar oberoende av v 5 väteatom eller en lägre alkyl, X är en halogene eller en väteatom, Y är en halogenatom, trifluorr en väteatom och A är en (C^) alkylen som eventuel stituerad med hydroxyl, eller ett farmakologiskt < sait därav för framställning av ett medel för pro: 10 behandling av arteriosclerosis obliterans, diabetii ee*j* ti, diabetisk neuropati eller hyper tr iglyceridemi : diabetes. • · 4 4 4 4 4 4
.* ,* 2. Användning enligt patentkrav 1, känneteckiu 4 4 4 • ] pyridazinonföreningen är en tromboxan A2-syntetashä 4 4 4 4 4 4 4 4 4 :*·*: 15
3. Användning enligt patentkrav 1, käzmetecknad 4 formeln (I) R1 och R2 är vardera en väteatom, R3 s : atom eller en (C, J alkyl, X är en halogenatom, Y έ ··· * .···, genatom eller en väteatom och A är en (C^) -alkylei 4 4 ---- -> - - 15
4. Användning enligt patentkrav 1, käimeteckn pyridazinonföreningen med formeln (I) är: 4-bromo-6-(3-fenylpropoxi)-5-(3-pyridyImetylamino) ridazinon, 5 4-kloro-6-(3-fenylpropoxi)-5-(3-pyridylmetylamino) ridazinon, 4-kloro-6-[3-(4-klorofenyl)propoxi]-5-(3-pyridylme (2H)-pyridazinon, 4-bromo-6-[3-(4-klorofenyl)propoxi]-5-(3-pyridylme 10 3(2H)-pyridazinon, 4-bromo-6-(2,2-dimetyl-3-fenylpropoxi)-5-(3-pyridy no)-5-(3-pyridylmetylamino)-3-(2H)-pyridazinon, 4-kloro-6-(2,2-dimetyl-3-fenylpropoxi)-5-(3-pyridy no)-3(2H)-pyridazinon, 15 4-bromo-6-[3-(4-klorofenyl)-2,2-dimetylpropoxi]-5-metylamino)-3(2H)-pyridazinon, 4-kloro-6-[3-(4-klorofenyl)-2,2-dimetylpropoxi]-5-metylamino)-3(2H)-pyridazinon, 4-bromo-6-[3-(4-klorofenyl)-3-hydroxipropoxi]-5-(3 20 tylamino)-3(2H)-pyridazinon, 4-kloro-6-[3-(4-klorofenyl)-3-hydroxipropoxi-5-(3- Mf tylamino) -3 (2H) -pyridazinon, * · 1 *·:.· 4-bromo-6- [3- (4-klorofenyl) -2-hydroxipropoxi] -5- (3 • · tylamino) -3 (2H) -pyridazinon eller • 25 4-kloro-6-[3-(4-klorofenyl)-2-hydroxipropoxi]-5-(3 : tylamino)-3 (2H) -pyridazinon. Ml • 1· • 1 · * · ♦ » • ♦ · • ♦ · «M » • M
FI963264A 1994-02-22 1996-08-21 Användning av en pyridazinonförening för framställning av ett medel för profylax eller behandling av tromboxan A2-medlade sjukdomar FI116882B (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2455694 1994-02-22
JP2455694 1994-02-22
JP9500244 1995-02-20
PCT/JP1995/000244 WO1995022329A1 (en) 1994-02-22 1995-02-20 Agent for prophylaxis and treatment of thromboxane a2-mediated diseases

Publications (3)

Publication Number Publication Date
FI963264A FI963264A (sv) 1996-08-21
FI963264A0 FI963264A0 (sv) 1996-08-21
FI116882B true FI116882B (sv) 2006-03-31

Family

ID=12141437

Family Applications (1)

Application Number Title Priority Date Filing Date
FI963264A FI116882B (sv) 1994-02-22 1996-08-21 Användning av en pyridazinonförening för framställning av ett medel för profylax eller behandling av tromboxan A2-medlade sjukdomar

Country Status (16)

Country Link
US (1) US5798357A (sv)
EP (1) EP0744950B1 (sv)
JP (1) JP3858279B2 (sv)
KR (1) KR100345187B1 (sv)
CN (1) CN1084620C (sv)
AT (1) ATE273708T1 (sv)
AU (1) AU1718395A (sv)
CA (1) CA2183234C (sv)
DE (1) DE69533392T2 (sv)
DK (1) DK0744950T3 (sv)
ES (1) ES2222464T3 (sv)
FI (1) FI116882B (sv)
IL (1) IL112695A (sv)
NO (1) NO311490B1 (sv)
WO (1) WO1995022329A1 (sv)
ZA (1) ZA951470B (sv)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW482675B (en) * 1997-01-31 2002-04-11 Green Cross Corp Compositions for oral administration containing pyridazinone compounds technical field of the invention
JP4352613B2 (ja) 1997-08-28 2009-10-28 日産化学工業株式会社 血管新生促進剤及び血管新生作用増強剤
US6143113A (en) 1998-03-02 2000-11-07 Le Groupe Recherche I.D. Inc. Repulpable corrugated boxboard
AU5445699A (en) 1998-09-01 2000-03-21 Nissan Chemical Industries Ltd. Remedies for spinal canal stenosis
CZ20012020A3 (cs) * 1998-12-07 2001-10-17 Nissan Chemical Industries, Ltd. Činidlo pro léčbu erektilní dysfunkce
EP1698339A4 (en) * 2003-12-26 2009-06-17 Nissan Chemical Ind Ltd INHIBITOR OF NEUTROPHILY
CA2714160A1 (en) * 2008-01-29 2009-08-06 Indigo Pharmaceuticals A method of administering a pde3 inhibitor via titration for the treatment of peripheral arterial disease
CN113546049B (zh) * 2021-04-30 2023-03-17 贵州汉方药业有限公司 一种柔性丸剂药物黏合剂及使用该黏合剂制成的柔性丸剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599336A (en) * 1983-08-08 1986-07-08 Hoffmann-La Roche Inc. Derivatives of (E)-3-(4-oxo-4H-quinazolin-3-yl)-2-propenamide
EP0142057A3 (en) * 1983-11-04 1988-03-30 F. Hoffmann-La Roche Ag Thiazoloquinazoline derivatives, their preparation and pharmaceutical compositions containing same
US4978665A (en) * 1987-01-20 1990-12-18 Nissan Chemical Industries Ltd. 3(2H)pyridazinone, and antagonistic agent against SRS-A containing it
JPH02256668A (ja) * 1988-12-20 1990-10-17 Nissan Chem Ind Ltd ピリダジノン誘導体
KR970002876B1 (ko) * 1990-04-25 1997-03-12 닛산가가꾸고오교 가부시끼가이샤 피리다지논 유도체

Also Published As

Publication number Publication date
CN1141590A (zh) 1997-01-29
ZA951470B (en) 1995-12-07
WO1995022329A1 (en) 1995-08-24
EP0744950A1 (en) 1996-12-04
NO963463L (no) 1996-08-20
JPH07285869A (ja) 1995-10-31
DE69533392D1 (de) 2004-09-23
US5798357A (en) 1998-08-25
DE69533392T2 (de) 2005-09-01
ES2222464T3 (es) 2005-02-01
NO311490B1 (no) 2001-12-03
FI963264A (sv) 1996-08-21
IL112695A (en) 1999-04-11
DK0744950T3 (da) 2004-10-25
IL112695A0 (en) 1995-05-26
CA2183234C (en) 2004-05-04
EP0744950B1 (en) 2004-08-18
CA2183234A1 (en) 1995-08-24
FI963264A0 (sv) 1996-08-21
AU1718395A (en) 1995-09-04
KR100345187B1 (ko) 2002-12-05
CN1084620C (zh) 2002-05-15
KR970701048A (ko) 1997-03-17
ATE273708T1 (de) 2004-09-15
JP3858279B2 (ja) 2006-12-13

Similar Documents

Publication Publication Date Title
TWI226329B (en) Compounds of the formula I for the treatment of ischemia, and pharmaceutical composition comprising the same
KR100559192B1 (ko) 혈관신생 촉진제 및 혈관신생 작용증강제
PT1024138E (pt) Derivados de pirazole
TW201103916A (en) Pyrazoles as 11-beta-HSD-1
TW200804295A (en) Compounds useful in therapy
JPH11302277A (ja) ピラゾール誘導体、その製法および医薬としてのその使用
JP2003510359A (ja) 化合物および方法
CA2466813A1 (fr) Derives de benzimidazoles et leur utilisation comme inhibiteurs de proteine kinase kdr
FI116882B (sv) Användning av en pyridazinonförening för framställning av ett medel för profylax eller behandling av tromboxan A2-medlade sjukdomar
CA2656157A1 (en) Transcription factor modulating compounds and methods of use thereof
CA2494321C (en) 1,2,4-triazole derivative, method for preparing the same, and pharmaceutical composition containing the same
JP6247004B2 (ja) 帯状疱疹関連通の急性期疼痛の予防又は治療剤
TW201630607A (zh) 西格馬受體配位子於骨關節炎之用途
JP2001354658A (ja) ヒドロキシホルムアミジン化合物及びその塩並びにそれらを含む医薬
CN108601784A (zh) 药物
WO2002078696A1 (en) Compounds and methods
JP2003503389A (ja) ピラゾリジノール化合物
Thorin-Trescases et al. Vasorelaxant properties of isolated human internal mammary arteries and saphenous veins: comparative effects of milrinone and sodium nitroprusside
JP2003081830A (ja) 酸化ストレス抑制剤
HUT74693A (en) 3-aryl-4-alkyl and 4,5-dialkyl-4h-1,2,4-triazoles useful as memory enhancers
US20010047023A1 (en) New Heterocyclic compounds for therapeutic use
WO2002078697A1 (en) Compounds and methods
JP2004123700A (ja) パーオキシナイトライト消去剤
JPS63313784A (ja) 新規ピラゾール誘導体およびその製造法ならびにこれを有効成分とする抗潰瘍剤
AU2009209152A2 (en) A method of administering a PDE3 inhibitor via titration for the treatment of peripheral arterial disease

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD

FG Patent granted

Ref document number: 116882

Country of ref document: FI

MA Patent expired